Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05470699 · ClinicalTrials.gov registry record · NA
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
A NA study of Prostate Carcinoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05470699: Active NA study of Prostate Carcinoma, sponsored by City of Hope Medical Center.
NCT05470699 is a NA study of Prostate Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 34 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05470699, a NA study of Prostate Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial examines RefleXion Medical Radiotherapy System (RMRS) imaging to the standard of care (SOC) \[18F\]-DCFPyL positron emission tomography-computed tomography (PET-CT) imaging in patients with prostate cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of a tracer, \[18F\]-DCFPyL, that binds to prostate specific membrane antigen (PSMA) on tumor cells. These PSMA tumor cells can then be identified on PET imaging. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. The RMRS is a imaging-therapy combination system that can plan for and deliver radiation therapy as well perform \[18F\]-DCFPyL PET-CT imaging. Comparing the imaging from the standard of care \[18F\]-DCFPyL-PET-CT with the \[18F\]-DCFPyL imaging from RMRS may help improve the quality of the imaging captured and determine if imaging can be done on the RMRS at the same time as planning for radiation therapy, which would reduce the number of scans needed to plan for radiation for prostate cancer.
Primary Outcome
To determine imaging performance of the X1 PET scan, the number of tumors clearly visualized on PET scan were reported.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Fluorine F 18 Piflufolastat
- DEVICE Positron Emission Tomography
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2026-04-13 |
| Phase | NA |
What the registry record for NCT05470699 still lists
NCT05470699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.
NCT05470699 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05470699 about?
NCT05470699 is a clinical study titled "RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer". This clinical trial examines RefleXion Medical Radiotherapy System (RMRS) imaging to the standard of care (SOC) \[18F\]-DCFPyL positron emission tomography-computed tomography (PET-CT) imaging in patients with prostate cancer. PET is an established imaging technique that utilizes small amounts of ra...
What is the current status of trial NCT05470699?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2022-08-29. Estimated completion is 2026-04-13.
What conditions does trial NCT05470699 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT05470699?
The interventions under investigation include: Computed Tomography (PROCEDURE), Fluorine F 18 Piflufolastat (OTHER), Positron Emission Tomography (DEVICE).
Who is sponsoring clinical trial NCT05470699?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05470699 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05470699's enrollment target sits among peer trials
34 45th of 59 higher than 15 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
RECRUITING · NA
-
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
RECRUITING · NA
-
[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
RECRUITING · NA
-
Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy
RECRUITING · NA
-
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI